The test identifies genetic variants in GLP1R, GIPR, MC4R, and FTO genes that influence how your body responds to GLP-1 medications and peptide therapies
Visceral fat and hepatic fat accumulate and resolve through similar mechanisms
Someone stopping these medications doesnt have the same control over their obesity, and their weight can increase. What to expect Nearly 12% of Americans about one in eight have used GLP-1 drugs for weight loss, according to a 2025 report from RAND, a nonprofit research organization
Healthcare professionals must carefully weigh potential benefits against risks, ensure appropriate monitoring, and maintain realistic expectations about outcomes
WeightWatchers is a human-centric technology company powered by our proven, science-based, clinically effective weight loss and weight management programs
NIH.gov Obesity Medicine Association